Gilead Sciences swung to a $10,496 million net loss for the three months ended June 30, 2026 — negative $8.45 per share, against $1,960 million of profit a year earlier — and the operating business had almost nothing to do with it. Strip out the $11,183 million charge for acquired in-process research and development and a $1,750 million impairment, and product sales actually grew 8.1% to $7,627 million with gross margin expanding; on a non-GAAP basis the loss narrows to $6.75 per share. The loss is a U.S. accounting outcome, not a demand problem: Gilead bought three biotechs for roughly $11.2 billion of cash consideration — an $11,318 million investing outflow on the cash flow statement — and, because each was structured as an asset acquisition, GAAP required the in-process R&D portion of the purchase price to be expensed on day one rather than capitalized. Management's read of the underlying business was confident enough that it raised full-year guidance on the same day.
1. Balance Sheet: Cash Converted Into Expense
1-1. Major Asset Movements
| Item | Dec 31, 2025 ($M) | Jun 30, 2026 ($M) | Change % |
|---|---|---|---|
| Cash and cash equivalents | 7,564 | 3,179 | −58.0 |
| Marketable debt securities (ST + LT) | 3,042 | 0 | −100.0 |
| Accounts receivable, net | 4,913 | 5,055 | +2.9 |
| Inventories (current) | 1,774 | 1,953 | +10.1 |
| Property, plant and equipment, net | 5,606 | 5,833 | +4.0 |
| Intangible assets, net | 16,978 | 14,032 | −17.4 |
| Goodwill | 8,314 | 8,314 | 0.0 |
| Total assets | 59,023 | 49,362 | −16.4 |
Total assets fell $9,661 million in six months. Two lines explain nearly all of it. Gilead liquidated its entire $3,042 million marketable securities portfolio and drew cash down by $4,385 million to fund acquisitions. Combined liquidity — cash plus securities — went from $10,606 million to $3,179 million, a 70% reduction.
The intangible asset decline is a different story. Of the $2,946 million drop, $1,750 million came from writing off the indefinite-lived IPR&D asset tied to sacituzumab govitecan in non-small cell lung cancer. Gilead discontinued the Phase 3 EVOKE-03 study in June 2026 and concluded no future cash flows were expected. The remaining decline is routine amortization of $1,196 million across the sofosbuvir, Yescarta and Trodelvy intangibles. One offset: the $550 million bulevirtide IPR&D asset was reclassified into finite-lived assets after FDA granted Hepcludex accelerated approval in May.
Inventories deserve a footnote. The current balance rose 10.1%, but total inventory including the long-term portion held in Other long-term assets was $4,298 million at June 30 versus $4,368 million at December 31 — essentially flat, and slightly down. Gilead is holding $568 million of pre-commercial Trodelvy inventory for which FDA has not yet approved the manufacturing process.
1-2. Financial Debt vs. Operating Liabilities
Total debt, net rose to $26,246 million from $24,937 million. Gilead repaid $2.75 billion of 3.65% notes maturing in March 2026, then issued $3.0 billion of new senior unsecured notes in May and drew $1.1 billion on a one-year term loan facility in April. The refinancing cost is visible in the coupons. The new 2026 notes carry 4.25% to 4.90%; the 2020-vintage paper they sit beside carries 1.20% to 2.80%. Debt maturing within three years totals $4,592 million, or 18.2% of the $25,168 million notes-and-term-loan balance. The ladder is not front-loaded, but it deserves to be read against the other side of the balance sheet: $3,179 million of cash and no marketable securities left. Operating cash generation covers those maturities comfortably; the liquidity cushion by itself no longer does.
Operating liabilities moved the other way. Accounts payable, accrued rebates and other current liabilities together fell to $8,606 million from $9,005 million. Accrued rebates — the reserve for discounts owed to U.S. payers and government programs — declined 2.4% to $4,233 million even as U.S. product sales rose 11.2% to $5,601 million. Measured against annualized U.S. sales, the rebate accrual eased to roughly 19% from 22%. That can reflect a friendlier payer mix; it can equally reflect reserve releases flattering current margins. Gilead does not break out the drivers, so the line is worth watching rather than banking.
1-3. Capital Structure: The Retained Earnings Buffer Is Nearly Gone
Total stockholders' equity halved, from $22,618 million to $11,744 million. Retained earnings did the collapsing: $13,730 million down to $2,200 million, an 84.0% reduction. The quarter's bridge is arithmetic — $14,131 million at March 31, less the $10,496 million net loss, less $1,031 million of dividends declared, less $404 million charged for share repurchases and tax withholding.
Additional paid-in capital now stands at $9,532 million — $9,533 million including the $1 million of common stock at par — and crossed above retained earnings during the half; at December 31, 2025 it stood at $8,932 million against $13,730 million of retained earnings. Gilead is currently declaring about $1,030 million in dividends per quarter. At that pace the retained earnings balance covers roughly two more quarters before distributions begin drawing on other components of equity. This is an accounting observation, not a legal constraint — Delaware law permits dividends out of surplus — but it does mean any further large IPR&D write-off would push the line negative. Debt-to-equity moved from 1.10x to 2.23x on the same math.
2. Income Statement: The Underlying Business Accelerated
2-1. Reported Results
| Item | Q2 2025 ($M) | Q2 2026 ($M) | Change % |
|---|---|---|---|
| Product sales | 7,054 | 7,627 | +8.1 |
| Royalty, contract and other revenues | 27 | 176 | +551.9 |
| Total revenues | 7,082 | 7,803 | +10.2 |
| Cost of goods sold | 1,501 | 1,579 | +5.2 |
| Research and development | 1,491 | 1,764 | +18.3 |
| Acquired IPR&D | 61 | 11,183 | — |
| IPR&D impairments | 190 | 1,750 | — |
| Selling, general and administrative | 1,365 | 1,921 | +40.7 |
| Operating income (loss) | 2,474 | (10,394) | — |
| Net income (loss) | 1,960 | (10,496) | — |
| Diluted EPS ($) | 1.56 | (8.45) | — |
Gross margin on product sales improved to 79.3% from 78.7%. That is the cleanest signal in the filing — pricing and mix held while volume grew.
2-2. Separating One-Time From Recurring
Three acquisitions closed in the quarter: Arcellx in April for approximately $6.4 billion in cash net of cash acquired, Tubulis in May for approximately $3.2 billion on the same basis, and Ouro Medicines in June for aggregate consideration of approximately $1.9 billion — comprising $1.6 billion of cash plus contingent milestone consideration recorded at a $277 million fair value. That is roughly $11.2 billion of cash across the three, which is what shows up in the cash flow statement; the $1.9 billion headline for Ouro is a consideration figure, not a cash figure.
Because the lead asset represented substantially all of the fair value in each case, GAAP treats them as asset acquisitions, and IPR&D with no alternative future use must be expensed immediately. The gross charge was $12.0 billion — $7.0 billion for Arcellx, $3.1 billion for Tubulis and $1.9 billion for Ouro — reduced to $11,183 million after Lakefront Biotherapeutics (formerly Galapagos NV) paid Gilead $860 million for half the Ouro upfront under a collaboration deal.
A second, less obvious cost sits inside R&D and SG&A. Gilead cash-settled unvested employee stock awards at the three targets, producing $561 million of stock-based compensation — $229 million in R&D and $332 million in SG&A. That single item explains most of the SG&A jump. Here is the bridge:
| Operating income bridge — Q2 ($M) | 2025 | 2026 |
|---|---|---|
| Reported operating income (loss) | 2,474 | (10,394) |
| + Acquired IPR&D | 61 | 11,183 |
| + IPR&D impairments | 190 | 1,750 |
| + Acquisition-related stock compensation | — | 561 |
| Normalized operating income | 2,725 | 3,100 |
| Normalized operating margin | 38.5% | 39.7% |
On that basis operating profit rose 13.8% on 10.2% revenue growth. Operating leverage — the rate at which profit grows faster than sales — ran at about 1.35 times. Adjusting for the same items, R&D rose only 3.0% to $1,535 million and SG&A rose 16.4% to $1,589 million. The SG&A increase is real and reflects launch spending behind Yeztugo, Livdelzi and the expanded Trodelvy label.
For longer context, Gilead's total revenue was $27,116 million in FY2023, $28,754 million in FY2024 and $29,443 million in FY2025 — growth of 6.0% then 2.4%. First-half 2026 revenue of $14,763 million is up 7.4%, an acceleration against both prior years.
Management raised full-year 2026 guidance alongside the results. Product sales guidance moved to $30.1–30.4 billion from $30.0–30.4 billion, and the ex-Veklury range — the number that strips out COVID-era decay — moved up more meaningfully, to $29.8–30.1 billion from $29.4–29.8 billion. Non-GAAP EPS guidance improved to negative $0.65 to negative $0.30, from negative $1.05 to negative $0.65. It stays negative for the full year because the IPR&D charges are permanent, not a timing difference. Raising the top line in the same release that reports a $10.5 billion loss is the clearest available statement of which of the two numbers management thinks describes the business.
The tax line looks strange and is worth explaining. Gilead recorded $242 million of tax expense on a $10,254 million pre-tax loss, an effective rate of negative 2.4%. The acquired IPR&D charges are largely non-deductible, so the loss generated almost no tax shield.
3. Cash Flow: Operations Are Stronger Than the P&L Suggests
| Item — Six months ($M) | 2025 | 2026 | Change |
|---|---|---|---|
| Operating cash flow | 2,584 | 6,117 | +3,533 |
| Investing cash flow | (2,531) | (8,577) | −6,046 |
| Financing cash flow | (4,993) | (1,895) | +3,098 |
| Ending cash | 5,144 | 3,179 | — |
Operating cash flow more than doubled. Two adjustments make the comparison honest. The $860 million Lakefront payment landed in operating activities, not investing — the cash flow statement adds back the gross $12,150 million of acquired IPR&D for the half against the $11,290 million actually expensed on the income statement, and the $860 million difference is the reimbursement — so the underlying figure is closer to $5,257 million. And the prior-year period absorbed a $1,852 million income tax payment that did not repeat. Normalizing both sides still leaves 2026 well ahead of 2025.
Free cash flow — operating cash flow minus capital expenditure — was $5,860 million against $2,373 million. Capital spending of $257 million equals 1.7% of revenue, confirming this is a maintenance-level asset base rather than a build-out. The $11,318 million acquisition outflow sits in investing on a gross basis, which is why the P&L shows a catastrophe while cash from operations looks healthy.
Financing tells the capital allocation story. Gilead raised $4,085 million of new debt, repaid $2,783 million, paid $2,069 million of dividends and repurchased $774 million of stock. Buybacks fell 38.4% from $1,257 million a year earlier, while dividends rose 3.2%. Management protected the dividend, funded the deals partly with debt, and let repurchases absorb the squeeze. The quarterly dividend declared rose to $0.82 per share from $0.79.
4. What Else Matters
Product concentration remains the central risk. Biktarvy alone generated $3,772 million in the quarter — 49.5% of all product sales. The HIV franchise as a whole produced $5,693 million, or 74.6%. Growth was healthy at 11.9%, and Descovy surged 48.1% to $967 million. But a single molecule carrying half of revenue is a structural exposure, and Cipla filed a 505(b)(2) application in January 2026 with a paragraph IV certification challenging two Orange Book patents for Descovy. Gilead sued in the District of Delaware in February.
| Q2 product sales ($M) | 2025 | 2026 | Change % |
|---|---|---|---|
| Total HIV | 5,088 | 5,693 | +11.9 |
| — Biktarvy | 3,530 | 3,772 | +6.9 |
| — Descovy | 653 | 967 | +48.1 |
| — Yeztugo | 15 | 232 | — |
| Liver Disease | 795 | 877 | +10.3 |
| Veklury | 121 | 23 | −81.0 |
| Cell Therapy | 485 | 417 | −14.0 |
| Trodelvy | 364 | 457 | +25.5 |
| Total product sales | 7,054 | 7,627 | +8.1 |
Yeztugo is the growth engine to watch. The twice-yearly HIV prevention injection reached $232 million from $15 million a year ago, and $397 million across the first half. FDA has accepted a supplemental application for a once-weekly oral 300-mg formulation, with a PDUFA target action date of February 2, 2027. A separate filing for bictegravir plus lenacapavir in virologically suppressed patients carries a priority-review date of August 27, 2026.
Oncology is being rebuilt through the balance sheet. Cell Therapy fell 14.0% as Yescarta and Tecartus lost ground. Trodelvy grew 25.5% and won a first-line metastatic triple-negative breast cancer approval, but the EVOKE-03 lung cancer failure cost $1.75 billion. The three acquisitions — a BCMA CAR-T (anito-cel), a next-generation antibody-drug conjugate (TUB-040) and a T-cell engager (gamgertamig) — are all aimed at this gap.
R&D intensity is rising. Reported R&D reached 22.6% of revenue versus 21.1%. Including acquired IPR&D, Gilead committed roughly $12.9 billion to research in a single quarter — more than 1.6 times the quarter's entire revenue.
Receivable concentration. Approximately 60% of accounts receivable relates to three wholesalers — Cardinal Health, Cencora and McKesson — and their specialty distributor affiliates. This is normal for U.S. pharma but concentrates counterparty risk.
Litigation: no accrual is not the same as no exposure. Gilead reported no material accruals for the matters disclosed in the filing as of June 30, 2026. In the consolidated HIV antitrust class actions, the June 2023 jury verdict was returned in Gilead's favor on the remaining Phase I allegations; plaintiffs are appealing, oral argument was heard in October 2025, and the Phase II claims are stayed pending that appeal. Gilead had separately settled with the direct purchaser class and retailer opt-out plaintiffs for $525 million in May 2023. An Aetna opt-out suit covering Truvada and Atripla is scheduled for trial in January 2027. Beyond antitrust, product liability suits over Viread, Truvada, Atripla, Complera and Stribild involve approximately 23,000 plaintiffs, with a first federal bellwether trial set for March 2027. The zero accrual reflects management's judgment that losses are not yet probable and estimable — a judgment that can reverse in a single reporting period, and one that lands on an equity base already cut in half.